KR102489829B1 - Composition for sleeping induction comprising extracts of heukharang lettuce - Google Patents
Composition for sleeping induction comprising extracts of heukharang lettuce Download PDFInfo
- Publication number
- KR102489829B1 KR102489829B1 KR1020220038623A KR20220038623A KR102489829B1 KR 102489829 B1 KR102489829 B1 KR 102489829B1 KR 1020220038623 A KR1020220038623 A KR 1020220038623A KR 20220038623 A KR20220038623 A KR 20220038623A KR 102489829 B1 KR102489829 B1 KR 102489829B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- weight
- present
- sleep
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 241000208822 Lactuca Species 0.000 title claims abstract description 19
- 235000003228 Lactuca sativa Nutrition 0.000 title claims abstract description 19
- 230000006698 induction Effects 0.000 title description 5
- 230000001939 inductive effect Effects 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 16
- 229940026510 theanine Drugs 0.000 claims abstract description 8
- 241001512722 Ecklonia cava Species 0.000 claims abstract description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000001543 Corylus americana Nutrition 0.000 claims description 4
- 240000007582 Corylus avellana Species 0.000 claims description 4
- 235000007466 Corylus avellana Nutrition 0.000 claims description 4
- 235000015241 bacon Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 241000392544 Dendropanax morbifer Species 0.000 abstract 1
- 241000107363 Tylophora paniculata Species 0.000 abstract 1
- 241001505102 Valeriana fauriei Species 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 230000004622 sleep time Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- -1 and the like Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229940018973 ecklonia cava extract Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 수면유도용 조성물에 관한 것으로, 더욱 상세하게는 흑하랑상추 추출물을 활성성분으로 함유하는 수면유도용 조성물에 관한 것이다.The present invention relates to a composition for inducing sleep, and more particularly, to a composition for inducing sleep containing an extract of Heukharang lettuce as an active ingredient.
수면은 삶의 질을 평가하는 필수적인 건강 요소이다. 불면증(또는 수면 장애)는 항상성의 조절장애를 일으키고 염증 관련 질환 및 만성 질환에 취약해지도록 한다. 불면증은 성인의 12%에서 나타나는 흔한 증상이며 일차 진료기관에 방문하는 환자의 20%가 유의한 수면 이상을 호소한다고 한다. 수면제는 일반적으로 불면증의 단기적 치료에는 효과적일 수 있다. 이러한 수면장애의 치료제로는 쿠아제팜(quazepam), 플루라제팜(flurazepam) 및 트리아졸람(triazolam) 등의 벤조디아핀(benzodiapine) 계통 약물과 졸피뎀(zolpidem)이 있다. 이러한 약물의 단점은 불안, 흥분 및 금단현상과 유사한 증상이 나타날 수 있어, 일상생활의 어려움 뿐만 아니라 인지적 장애나 우울 등 다른 질병을 일으키는 위험요인이 되기도 한다. 따라서, 상기와 같은 약물을 대체하고 위험요소를 나타내지 않는 수면장애 치료제의 개발이 절실한 상황이다.Sleep is an essential health factor that evaluates the quality of life. Insomnia (or sleep disturbance) leads to dysregulation of homeostasis and susceptibility to inflammation-related diseases and chronic diseases. Insomnia is a common symptom in 12% of adults, and 20% of patients visiting primary care centers report significant sleep disturbances. Sleeping pills can be effective for the short-term treatment of insomnia in general. Treatments for these sleep disorders include benzodiapine drugs such as quazepam, flurazepam, and triazolam, and zolpidem. The disadvantage of these drugs is that symptoms similar to anxiety, excitement, and withdrawal may appear, which may cause not only difficulties in daily life, but also risk factors for other diseases such as cognitive impairment or depression. Therefore, there is an urgent need to develop a sleep disorder treatment agent that replaces the above drugs and does not present risk factors.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위하여 제안된 것으로, 흑하랑상추 추출물을 활성성분으로 함유하는 수면유도용 조성물을 제공함에 있다. The present invention has been proposed to solve the above-mentioned problems of the prior art, and is to provide a sleep inducing composition containing a black harang lettuce extract as an active ingredient.
본 발명의 해결하고자 하는 과제는 이상에서 언급한 것으로 제한되지 않으며, 언급되지 않은 또 다른 해결하고자 하는 과제는 아래의 기재로부터 본 발명이 속하는 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.The problem to be solved by the present invention is not limited to those mentioned above, and another problem to be solved that is not mentioned will be clearly understood by those skilled in the art from the description below.
상기한 바와 같은 본 발명의 기술적 과제는 다음과 같은 수단에 의해 달성되어진다.The technical problem of the present invention as described above is achieved by the following means.
(1) 흑하랑상추 추출물을 활성성분으로 함유하는 수면유도용 조성물.(1) A composition for inducing sleep containing an extract of black hazel lettuce as an active ingredient.
(2) 상기 (1)에 있어서,(2) In the above (1),
산해박 추출물을 더 포함하는 것을 특징으로 하는 수면유도용 조성물.A composition for inducing sleep, characterized in that it further comprises an extract of wild sea basil.
(3) 상기 (2)에 있어서,(3) In the above (2),
트립토판을 더 포함하는 것을 특징으로 하는 수면유도용 조성물.A composition for inducing sleep, characterized in that it further comprises tryptophan.
(4) 상기 (2)에 있어서,(4) In the above (2),
지오줌풀, 감태, 황칠나무, 및 테아닌으로 이루어진 군에서 선택된 적어도 1종의 추출물을 더 포함하는 것을 특징으로 하는 수면유도용 조성물.A composition for inducing sleep, characterized in that it further comprises at least one extract selected from the group consisting of geozumpul, Ecklonia cava, hwangchil tree, and theanine.
(5) 상기 (4)에 있어서,(5) In the above (4),
지오줌풀, 감태, 황칠나무, 및 테아닌의 추출물을 더 포함하는 것을 특징으로 하는 수면유도용 조성물.A composition for inducing sleep, characterized in that it further comprises extracts of geozumium, Ecklonia cava, hwangchil tree, and theanine.
(6) 상기 (1)에 있어서,(6) In the above (1),
상기 조성물은 식품조성물 혹은 약제학적 조성물인 것을 특징으로 하는 수면유도용 조성물.The composition is a composition for inducing sleep, characterized in that the food composition or pharmaceutical composition.
상술한 바와 같이 본 발명은 기존의 수면제를 대체할 수 있고, 천연물로 구성되어 안전한 흑하랑상추 추출물을 활성성분으로 함유하는 수면유도용 조성물을 제공한다.As described above, the present invention provides a sleep-inducing composition containing, as an active ingredient, a safe Black Harang lettuce extract, which can replace existing sleeping pills and is composed of a natural product.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있으며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and how to achieve them, will become clear with reference to the detailed description of the following embodiments. However, the present invention is not limited to the embodiments disclosed below, but may be implemented in various different forms, and only these embodiments make the disclosure of the present invention complete, and common knowledge in the art to which the present invention belongs. It is provided to completely inform the person who has the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명의 실시예들을 설명함에 있어서 공지 기능 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략할 것이다. 그리고 후술되는 용어들은 본 발명의 실시예에서의 기능을 고려하여 정의된 용어들로서 이는 사용자, 운용자의 의도 또는 관례 등에 따라 달라질 수 있다. 그러므로 그 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다. In describing the embodiments of the present invention, if it is determined that a detailed description of a known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted. In addition, terms to be described later are terms defined in consideration of functions in the embodiment of the present invention, which may vary according to the intention or custom of a user or operator. Therefore, the definition should be made based on the contents throughout this specification.
이하, 본 발명의 내용을 보다 상세하게 설명하면 다음과 같다.Hereinafter, the content of the present invention will be described in more detail.
본 발명에 따른 수면유도용 조성물은 흑하랑상추 추출물을 활성성분으로 함유한다. 흑하랑상추 추출물은 조성물의 중량을 기준으로 0.1~99중량% 포함될 수 있으며, 액상 혹은 분말 형태일 수 있다.The sleep inducing composition according to the present invention contains black harang lettuce extract as an active ingredient. The black haranguang lettuce extract may be included in an amount of 0.1 to 99% by weight based on the weight of the composition, and may be in liquid or powder form.
바람직하게는 상기 본 발명에 따른 수면유도용 조성물은 산해박 추출물을 더 포함한다. 산해박 추출물은 바람직하게는 1~5 중량% 첨가되며, 흑하랑상추 추출물의 쓴맛을 차폐하여 부드러운 맛을 부여하고, 수면유도 내지 진정작용에 상승효과를 제공한다.Preferably, the composition for inducing sleep according to the present invention further comprises an extract of Sanhaebaek. The mountain sea bacon extract is preferably added in an amount of 1 to 5% by weight, and provides a soft taste by shielding the bitter taste of the black harang lettuce extract, and provides a synergistic effect on sleep induction or sedation.
바람직하게는 상기 본 발명에 따른 수면유도용 조성물은 트립토판을 더 포함한다. 트립토판은 바람직하게는 1~10 중량% 첨가되며, 흑하랑상추 추출물과 함께 수면유도 내지 진정작용에 상승효과를 제공한다.Preferably, the sleep inducing composition according to the present invention further comprises tryptophan. Tryptophan is preferably added in an amount of 1 to 10% by weight, and provides a synergistic effect on sleep induction or sedation along with the black harangu lettuce extract.
바람직하게는 상기 본 발명에 따른 수면유도용 조성물은 지오줌풀, 감태, 황칠나무, 및 테아닌으로 이루어진 군에서 선택된 적어도 1종의 추출물을 더 포함한다. 본 발명에 따른 수면유도용 조성물은 보다 바람직하게는 지오줌풀, 감태, 황칠나무, 및 테아닌의 추출물을 포함한다. 상기 추출물은 흑하랑상추 추출물과 함께 수면유도 내지 진정작용에 상승효과를 제공한다.Preferably, the sleep inducing composition according to the present invention further includes at least one extract selected from the group consisting of geojumpul, Ecklonia cava, hwangchil tree, and theanine. The sleep inducing composition according to the present invention more preferably includes extracts of geojumpul, Ecklonia cava, hwangchil tree, and theanine. The extract provides a synergistic effect on sleep induction or sedation along with the black harangu lettuce extract.
상기 본 발명에 따른 각 추출물은 물추출물, 에탄올 추출물 또는 주정을 이용한 추출물이다.Each extract according to the present invention is a water extract, an ethanol extract, or an extract using alcohol.
또한, 본 발명에서는 상기 각 추출물의 유기용매 분획물이 수면유도용 조성물에 포함될 수 있다. 이때 사용가능한 유기용매로는 클로로포름 또는 에틸아세테이트를 들 수 있으며, 이들은 단독으로 또는 혼합용매로써 사용하여도 좋다. 혼합용매로 사용할 경우에는 클로로포름대 에틸아세테이트의 배합비는 중량비로 10~90 내지 90~10의 범위로 사용하면 좋다.In addition, in the present invention, the organic solvent fraction of each extract may be included in the sleep inducing composition. At this time, examples of the usable organic solvent include chloroform or ethyl acetate, and these may be used alone or as a mixed solvent. When used as a mixed solvent, the mixing ratio of chloroform to ethyl acetate may be used in the range of 10 to 90 to 90 to 10 in terms of weight ratio.
본 발명에서는 상기 추출물 또는 분획물은 그 자체로 사용되어도 좋고, 추출물과 분획물을 혼합하여 사용하여도 좋다. 이때 혼합비는 특별히 한정되는 것은 아니며, 예를 들어 중량비로 10~90 내지 90~10의 범위로 사용하면 좋다.In the present invention, the extract or fraction may be used as such, or may be used in combination with the extract and fraction. At this time, the mixing ratio is not particularly limited, and may be used, for example, in the range of 10 to 90 to 90 to 10 in terms of weight ratio.
상기 본 발명에 따른 수면유도용 조성물은 식품조성물 혹은 약제학적 조성물일 수 있다.The sleep inducing composition according to the present invention may be a food composition or a pharmaceutical composition.
상기 본 발명에 따른 수면유도용 조성물은 정제, 레커칠된 정제, 당 코팅된 정제, 경질 및 연질 캡슐, 용액, 에멀젼 또는 현탁액의 형태로서 경구적으로 투여될 수 있다. 이러한 형태의 제제는 비경구적으로도 투여될 수 있다. 예를 들어, 주사액의 형태로 비경구적으로도 투여될 수 있다. 활성성분은 위와 같은 경구 또는 비경구 투여제의 제형으로 각 활성 성분 모두를 함유하는 형태로 제형화되거나, 함께 또는 순차적으로 투여될 수 있는 단일 물질의 특별한 조합으로 개별적으로 투여될 수도 있다. 정제, 래커칠된 정제, 당 코팅된 정제 및 캡슐을 제조하기 위하여, 약제학적으로 불활성인 무기 또는 유기 부형제가 본 발명의 제형을 위해 첨가될 수 있다. 이러한 부형제로는 락토스, 옥수수전분 또는 이들의 유도체, 활석, 스테아르산 또는 이들의 염을 들 수 있다. 상기 캡슐에 적합한 부형제로는 식물성유, 왁스, 지방, 반고체 또는 액체 폴리올을 들 수 있다. 용액 및 시럽을 제조하는데 적절한 부형제는 예를 들어, 물, 폴리올, 수크로스, 전화당글루코스 등이다. 주사액에 적합한 부형제로는 물, 알코올, 글리세롤, 식물성유를 들 수 있다. The sleep inducing composition according to the present invention may be administered orally in the form of tablets, lacquered tablets, sugar-coated tablets, hard and soft capsules, solutions, emulsions or suspensions. Formulations of this type may also be administered parenterally. It can also be administered parenterally, for example in the form of an injectable solution. The active ingredients may be formulated in a form containing all of the respective active ingredients in a formulation for oral or parenteral administration as described above, or may be administered individually as a special combination of single substances that may be administered together or sequentially. To prepare tablets, lacquered tablets, sugar coated tablets and capsules, pharmaceutically inert inorganic or organic excipients may be added to the formulations of the present invention. Such excipients include lactose, corn starch or derivatives thereof, talc, stearic acid or salts thereof. Suitable excipients for the capsule include vegetable oils, waxes, fats, semi-solid or liquid polyols. Excipients suitable for preparing solutions and syrups are, for example, water, polyols, sucrose, invert glucose and the like. Suitable excipients for injection solutions include water, alcohol, glycerol, and vegetable oil.
또한 본 발명에 따른 제형은 필요에 따라 방부제, 용해제, 안정화제, 습윤제, 유화제, 감미제, 착색제, 향미제, 삼투압 조절제, 완충제, 코팅제 및/또는 산화방지제를 추가로 함유할 수 있다.In addition, the formulation according to the present invention may further contain a preservative, a solubilizer, a stabilizer, a wetting agent, an emulsifier, a sweetener, a colorant, a flavoring agent, an osmotic pressure regulator, a buffer, a coating agent, and/or an antioxidant, if necessary.
본 발명 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 본 발명의 경우 1일 0.0001 내지 100mg/kg으로, 바람직하게는 0.001 내지 100mg/kg으로 투여하는 것이 좋으며, 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다.The preferred dosage of the composition of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the drug type, the route and duration of administration, but can be appropriately selected by those skilled in the art. In the case of the present invention, it is recommended to administer 0.0001 to 100 mg/kg per day, preferably 0.001 to 100 mg/kg, and may be administered once a day or divided several times.
또한, 본 발명은 상기 추출물을 포함하는 식품조성물을 포함한다. 상기 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강보조식품 조성물의 경우는 전체 식품 중량의 0.1 내지 20 중량%, 바람직하게는 1 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물에는 100 ㎖를 기준으로 1 내지 25 g, 바람직하게는 2 내지 15 g의 비율로 가할 수 있다. 본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 액체성분에는 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리스리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등), 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. In addition, the present invention includes a food composition containing the extract. Foods to which the extract can be added include, for example, various foods, beverages, chewing gum, tea, vitamin complexes, health supplements, and the like. At this time, the amount of the extract in the food or beverage is generally 0.1 to 20% by weight, preferably 1 to 15% by weight of the total food weight in the case of the health supplement composition of the present invention, and in the health drink composition It may be added at a rate of 1 to 25 g, preferably 2 to 15 g, based on 100 ml. The health beverage composition of the present invention is not particularly limited in the liquid component except for containing the extract as an essential component in the indicated ratio, and may contain various flavors or natural carbohydrates as additional components like conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (eg rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. there is.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부당 0 내지 약 30 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its It may contain salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the compositions of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from the range of 0 to about 30 parts by weight per 100 parts by weight of the composition of the present invention.
이하 본 발명의 내용을 실시예를 참조하여 보다 구체적으로 설명하고자 하나 이들 실시예는 본 발명의 이해를 돕기 위해 제시된 것일 뿐 본 발명의 권리범위가 이에 한정되는 것으로 해석되어져서는 아니될 것이다.Hereinafter, the content of the present invention will be described in more detail with reference to examples, but these examples are only presented to aid understanding of the present invention and should not be construed as limiting the scope of the present invention thereto.
[실시예 1][Example 1]
흑하랑상추를 분쇄한 후 80℃ 열수에 24시간 동안 침지하여 액상의 열수추출물을 얻었고, 감압농축하여 흑하랑상추 추출물(25 Brix)을 얻었다. 상기 흑하랑상추 추출물(25 Brix) 5중량%, 산해박 열수추출물(25 Brix) 5중량%, 및 잔량의 정제수를 혼합하여 수면유도용 조성물을 제조하였다. After pulverizing the black hazel lettuce, it was immersed in 80° C. hot water for 24 hours to obtain a liquid hot water extract, and concentrated under reduced pressure to obtain a black harangu lettuce extract (25 Brix). A sleep inducing composition was prepared by mixing 5% by weight of the black haranguang lettuce extract (25 Brix), 5% by weight of the hot water extract of Sanhaebak (25 Brix), and the remaining amount of purified water.
[실시예 2][Example 2]
실시에 1의 조성에 트립토판 1중량%를 혼합한 것을 제외하고 실시예 1과 동일한 방법에 의해 수면유도용 조성물을 제조하였다.A composition for inducing sleep was prepared in the same manner as in Example 1, except that 1% by weight of tryptophan was mixed with the composition of Example 1.
[실시예 3][Example 3]
실시에 1의 조성에 지오줌풀 열수추출물(25 Brix) 5중량%를 혼합한 것을 제외하고 실시예 1과 동일한 방법에 의해 수면유도용 조성물을 제조하였다.A composition for inducing sleep was prepared in the same manner as in Example 1, except that 5% by weight of the hot water extract (25 Brix) was mixed with the composition of Example 1.
[실시예 4][Example 4]
실시에 1의 조성에 감태 열수추출물(25 Brix) 1중량%를 혼합한 것을 제외하고 실시예 1과 동일한 방법에 의해 수면유도용 조성물을 제조하였다.A sleep inducing composition was prepared in the same manner as in Example 1, except that 1% by weight of Ecklonia cava extract (25 Brix) was mixed with the composition of Example 1.
[실시예 5][Example 5]
실시에 1의 조성에 황칠나무 열수추출물(25 Brix) 1중량%를 혼합한 것을 제외하고 실시예 1과 동일한 방법에 의해 수면유도용 조성물을 제조하였다. A sleep inducing composition was prepared in the same manner as in Example 1, except that 1% by weight of hwangchil tree hot water extract (25 Brix) was mixed with the composition of Example 1.
[실시예 6][Example 6]
실시에 1의 조성에 테아닌(25 Brix) 0.5중량%를 혼합한 것을 제외하고 실시예 1과 동일한 방법에 의해 수면유도용 조성물을 제조하였다. A composition for inducing sleep was prepared in the same manner as in Example 1, except that 0.5% by weight of theanine (25 Brix) was mixed with the composition of Example 1.
[실시예 7][Example 7]
실시에 2의 조성에 지오줌풀 열수추출물(25 Brix) 5중량%, 감태 열수추출물(25 Brix) 1중량%, 황칠나무 열수추출물(25 Brix) 1중량%, 및 테아닌(25 Brix) 0.5중량%를 혼합한 것을 제외하고 실시예 2와 동일한 방법에 의해 수면유도용 조성물을 제조하였다. In the composition of Example 2, 5% by weight of geozoompul hot-water extract (25 Brix), 1% by weight of Ecklonia cava hot-water extract (25 Brix), 1% by weight of Hwangchil tree hot-water extract (25 Brix), and 0.5% by weight of theanine (25 Brix) A composition for inducing sleep was prepared in the same manner as in Example 2, except that the mixture was mixed.
[실험예 1] 수면실험[Experimental Example 1] Sleep Experiment
수면유도 시험 동물로는 체중 17.5 g의 ICR 수컷 마우스를 사용하였다. 사육 조건은 22℃, 상대습도 55%, 환기횟수 시간당 11회, 명암주기 12시간으로 유지하고, 모든 실험동물은 실험 동물실에서 1주일 간 적응시킨 후 실험에 사용하였다. 시료는 1일 1회(투여량: 20mg/kg)로 5일간 투여하였고, 최종 시료의 경구투여 45분 후에 펜토바르비탈(30mg/kg, i.p.)을 마우스 복강으로 주사하여 수면시간(sleeping time)과 입면시간(sleep latency)을 측정하였다.As sleep induction test animals, ICR male mice weighing 17.5 g were used. Breeding conditions were maintained at 22 ° C, relative humidity 55%, ventilation frequency 11 times per hour, light-dark cycle 12 hours, and all experimental animals were acclimatized in the laboratory animal room for 1 week and then used in the experiment. The sample was administered once a day (dosage: 20mg/kg) for 5 days, and 45 minutes after oral administration of the final sample, pentobarbital (30mg/kg, i.p.) was injected intraperitoneally to determine the sleeping time. and sleep latency were measured.
상기 각 실시예에 의해 제조한 수면유도 조성물과, 흑하랑상추 추출물만을 10중량% 조성한 비교예 각각을 상기 방법과 같이 투여한 후에 수면시간과 입면시간의 변화를 측정한 결과를 하기 표 1에 나타내었다.Table 1 shows the results of measuring the change in sleep time and elevation time after administering the sleep inducing composition prepared in each of the above examples and the comparative example in which only 10% by weight of the black harangu lettuce extract was administered in the same manner as described above. was
상기 실시예 1~7에서와 같이 본 발명 수면유도용 조성물을 투여한 마우스의 경우, 시료 투여에 의한 수면시간이 비교예에 비하여 현저히 증가하였고, 입면시간의 감소효과를 측정한 결과, 수면시간의 증대효과와 동일 양상으로 본 발명 실시예 조성물 투여의 경우가 비교예에 비하여 입면시간의 감소 효과가 현저한 것으로 나타났다.In the case of mice administered with the sleep inducing composition of the present invention as in Examples 1 to 7, the sleep time by sample administration was significantly increased compared to the comparative example, and as a result of measuring the effect of reducing the sleeping time, the sleep time In the same aspect as the augmenting effect, the case of administering the composition of the examples of the present invention showed a remarkable effect of reducing the elevation time compared to the comparative example.
[실험예 2][Experimental Example 2]
평상시의 수면 습관 등을 통하여 수면장해가 있는 40명의 대상자를 선별하여 8개 군으로 나누어 본 발명 실시예 1 내지 7 및 비교예 조성물을 복용(투여량: 20mg/kg)하게 한 후, 복용한 다음날에 전날의 수면에 관련된 사항을 설문조사로 평가하도록 하였다. 실험은 1주간 진행하였으며, 결과는 하기 표 3과 같다.After selecting 40 subjects with sleep disorders through their usual sleep habits, dividing them into 8 groups, and taking the compositions of Examples 1 to 7 and Comparative Example of the present invention (dosage: 20 mg/kg), the next day after taking them were asked to evaluate matters related to the previous night's sleep through a questionnaire survey. The experiment was conducted for 1 week, and the results are shown in Table 3 below.
상기의 결과에서 알 수 있는 바와 같이, 본 발명 실시예 조성물을 복용한 후 취침 전 잠들기가 개선됨을 알 수 있었으며, 비교예 조성물 투여군에 비하여 잠들기가 상당히 더 개선됨을 확인할 수 있었다.As can be seen from the above results, it was confirmed that the ability to fall asleep before going to bed was improved after taking the composition of the examples of the present invention, and that the ability to fall asleep was significantly improved compared to the group administered with the composition of the comparative example.
이상의 설명은 본 발명의 기술 사상을 예시적으로 설명한 것에 불과한 것으로서, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 다양한 수정 및 변형이 가능할 것이다. 따라서, 본 발명에 개시된 실시예들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다. 본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.The above description is merely an example of the technical idea of the present invention, and various modifications and variations can be made to those skilled in the art without departing from the essential characteristics of the present invention. Therefore, the embodiments disclosed in the present invention are not intended to limit the technical idea of the present invention, but to explain, and the scope of the technical idea of the present invention is not limited by these embodiments. The protection scope of the present invention should be construed according to the claims below, and all technical ideas within the scope equivalent thereto should be construed as being included in the scope of the present invention.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220038623A KR102489829B1 (en) | 2022-03-29 | 2022-03-29 | Composition for sleeping induction comprising extracts of heukharang lettuce |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220038623A KR102489829B1 (en) | 2022-03-29 | 2022-03-29 | Composition for sleeping induction comprising extracts of heukharang lettuce |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102489829B1 true KR102489829B1 (en) | 2023-01-18 |
Family
ID=85106585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220038623A KR102489829B1 (en) | 2022-03-29 | 2022-03-29 | Composition for sleeping induction comprising extracts of heukharang lettuce |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102489829B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150005482A (en) * | 2014-10-13 | 2015-01-14 | 재단법인 전남생물산업진흥원 | Composition containing extract of dendropanax morbifera the improvement and remedial of insominia |
-
2022
- 2022-03-29 KR KR1020220038623A patent/KR102489829B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150005482A (en) * | 2014-10-13 | 2015-01-14 | 재단법인 전남생물산업진흥원 | Composition containing extract of dendropanax morbifera the improvement and remedial of insominia |
Non-Patent Citations (3)
| Title |
|---|
| 열대야에 잠 못 이루는 밤...수면제 대신 감태·쥐오줌풀. 헤럴드경제. [online], 2019.07.24., [2022.07.17. 검색], 인터넷: <URL: http://news.heraldcorp.com/view.php?ud=20190724000482> 1부.* * |
| 원진배 외 4인. 서장경으로부터 분리한 Homosyringaldehyde의 뇌신경세포 보호 활성. 약학회지. 제56권, 제5호, pp. 299~303(2012) 1부.* * |
| 이너셋 :: 1월 신제품 쿨잠부루수도 곧 출시됩니다 :D. 네이버블로그. [online], 2020.01.19. [2022.07.17. 검색], 인터넷: <URL: https://blog.naver.com/ahyoung0127/221777994162> 1부.* * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1757324A2 (en) | Agent for preventing, improving or treating hypertension | |
| KR20110115862A (en) | Composition for reliving and preventing hangover and beverage comprising composition | |
| WO2013051727A1 (en) | Agent for improving quality of sleep | |
| US10201579B2 (en) | Compositions for reducing environmental sensitivity and regulating immune function | |
| KR102489829B1 (en) | Composition for sleeping induction comprising extracts of heukharang lettuce | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR20090045721A (en) | Compositions for improving sleep disturbance | |
| KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
| KR102328808B1 (en) | Composition for preventing and improving sarcopenia using brewer's yeast | |
| KR101880245B1 (en) | Food Composition for Anti-stress effect | |
| KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
| KR20040052930A (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
| KR102245027B1 (en) | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient | |
| KR20180058997A (en) | Pharmaceutical composition and food composition for preventing the growth of white hair or promoting the growth of black hair, and a process for preparing them | |
| WO2012056475A2 (en) | Composition for improving sexual health | |
| KR20210147707A (en) | Composition for relieving and preventing hangover comprising Oenanthe javanica extracts | |
| KR101568044B1 (en) | Composition reducing anxiety and stress | |
| KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
| KR102656187B1 (en) | Pharmaceutical composition for preventing or treating tuberculosis disease comprising Agastache rugosa extract as effective component | |
| KR20190016013A (en) | Composition for anti-stress effect, Functional Food and Pharmaceutical composition including the same | |
| KR102264608B1 (en) | Oral spray composition for suppressing appetite containing Ephedra sinica extract | |
| KR102681562B1 (en) | Composition for preventing, ameliorating or treating tuberculosis disease comprising Astilbe rubra var. rubra extract as effective component | |
| KR102329246B1 (en) | Composition of food or pharmacy for inducing sleep of good quality | |
| KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
| KR20240141381A (en) | Pharmaceutical composition for preventing or treating tuberculosis disease comprising Atractylodis Rhizoma Alba extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |